Edward Charles Dempsey
Physician in Denver, CO

License number
Colorado 28083
Issued Date
May 8, 1987
Renew Date
May 1, 2015
Expiration Date
Apr 30, 2017
Type
Physician
Address
Address
12700 E 19 St Rc2 B133 Univ Of Colorado Anschutz Med Campus, Denver, CO 80045

Professional information

Edward C Dempsey Photo 1

Dr. Edward C Dempsey, Aurora CO - MD (Doctor of Medicine)

Specialties:
Critical Care Medicine, Pulmonology
Address:
12605 E 16 Ave, Aurora 80045
(720) 848-5300 (Phone)
Certifications:
Critical Care Medicine, 1989, Internal Medicine, 1986, Pulmonary Disease, 1988
Awards:
Healthgrades Honor Roll
Languages:
English
Hospitals:
12605 E 16 Ave, Aurora 80045
University of Colorado Hospital - Anschutz Inpatient Pavilion
12605 East 16 Ave, Aurora 80045
Education:
Medical School
Harvard Medical School
Graduated: 1982
Yale-New Haven Medical Center Program
University Of Colorado (University Hospital) Program


Edward C Dempsey Photo 2

Edward C Dempsey, Aurora CO

Specialties:
Pulmonologist
Address:
12605 E 16Th Ave, Aurora, CO 80045
12700 E 19Th Ave, Aurora, CO 80045
Education:
Harvard Medical School - Doctor of Medicine
University of Colorado Hospital-Anschutz Inpatient Pavilion - Fellowship - Pulmonary Disease and Critical Care Medicine (Internal Medicine)
Yale New Haven Psychiatric Hospital - Residency - Internal Medicine
Board certifications:
American Board of Internal Medicine Certification in Internal Medicine, American Board of Internal Medicine Sub-certificate in Pulmonary Disease (Internal Medicine)


Edward Dempsey Photo 3

Treatment Of Pulmonary Vascular Remodeling With Neprilysin

US Patent:
2012012, May 17, 2012
Filed:
Sep 1, 2011
Appl. No.:
13/224126
Inventors:
Edward C. Dempsey - Aurora CO, US
International Classification:
A61K 38/48, A61P 11/00, A61P 9/00, A61P 9/12, G01N 33/573, C12Q 1/68, C12Q 1/37, A61K 48/00, A61P 29/00
US Classification:
424 9467, 514 44 R, 435 74, 435 613, 435 612, 435 23, 435 618
Abstract:
The present invention relates to agonists of Neprilysin and their use in preventing and treating pulmonary vascular remodeling. Also described are diagnostic and screening applications stemming from the inventor's discovery that Neprilysin is expressed at reduced levels in disease tissues.


Edward Dempsey Photo 4

Method Of Using Pkc Inhibiting Compounds To Treat Vascular Disease

US Patent:
6228843, May 8, 2001
Filed:
Apr 21, 2000
Appl. No.:
9/557038
Inventors:
Edward C. Dempsey - Denver CO
Assignee:
University Technology Corporation - Boulder CO
International Classification:
A01N 4304
US Classification:
514 31
Abstract:
A method for treating pulmonary and systemic vascular diseases associated with cardiac hypotrophy, dysfunction or failure that involves the administration of an effective amount of a PKC antagonist to a patient suffering from one of such diseases is disclosed. PKC antagonists are selected from bryostatin derivatives and more preferably from bryostatin-1. The disease states treatable in accordance with the present invention are characterized by alterations in vascular structure, vascular tone, myocardial hypotrophy, dysfunction or failure, idiopathic pulmonary hypertension and chronic hypoxic pulmonary hypertension. Particular formulations include bryostatin-1 in an effective amount to treat one or more of the above-referenced diseases.